Literature DB >> 3761443

Long-term followup of young patients with stage A adenocarcinoma of the prostate.

M L Blute, H Zincke, G M Farrow.   

Abstract

A total of 23 men less than 60 years old with stage A adenocarcinoma of the prostate who were managed expectantly (that is untreated) and were at risk for 10 to 25 years form the basis of this study. The original amount of tissue obtained at transurethral resection, number of chips involved and examined, and tumor grade (Mayo grades 1 to 4) were recorded and compared in an in-depth analysis whereby the entire tissue removed was examined without knowledge of previous grading attempts. On the basis of volume estimation of the amount of cancer present 8 patients were reclassified as having stage A2 disease. Of these 8 patients 2 had disease progression and 1 died of metastatic adenocarcinoma of the prostate. At review 15 patients remained with stage A1 disease and 4 had disease progression (3 systemically and 1 locally) an average of 10.2 years after diagnosis. Because of longer life expectancy the young patient with stage A1 disease is at increased risk for local and/or systemic disease progression. Therefore, when incidental adenocarcinoma of the prostate is found in young patients consideration should be given to examination of all tissue resected, and to repeat transurethral resection and biopsy to ensure accurate staging. Lifelong careful followup is mandatory not only to detect local recurrence owing to heterogeneous adenocarcinoma of the prostate but also to detect a possible secondary clinical lesion.

Entities:  

Mesh:

Year:  1986        PMID: 3761443     DOI: 10.1016/s0022-5347(17)45098-1

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  Comparative clinical features of stage A1 and stage A2 prostate cancers. Is the concept of stage A changing from the current status?

Authors:  K Kunimi; T Amano; S W Lee; H Fuse; T Uchibayashi; K Miyazaki; M Ohkawa
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

Review 2.  ACP Broadsheet No 146: August 1995. Macroscopic examination of prostatic specimens.

Authors:  P Harnden; M C Parkinson
Journal:  J Clin Pathol       Date:  1995-08       Impact factor: 3.411

3.  Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging.

Authors:  Aytekin Oto; Arda Kayhan; Yulei Jiang; Maria Tretiakova; Cheng Yang; Tatjana Antic; Farid Dahi; Arieh L Shalhav; Gregory Karczmar; Walter M Stadler
Journal:  Radiology       Date:  2010-09-15       Impact factor: 11.105

4.  The prognosis of stage A patients treated with the antiandrogen chlormadinone acetate.

Authors:  Y Kubota; T Nakada; I Sasagawa; H Yanai; K Itoh; H Suzuki
Journal:  Int Urol Nephrol       Date:  1999       Impact factor: 2.370

5.  Diagnosis, prognosis and management of incidentally found prostate cancer.

Authors:  P J Davidson
Journal:  Urol Res       Date:  1993-01

6.  Long-term survival of stage A prostate carcinoma, atypical hyperplasia/adenosis and BPH.

Authors:  P N Brawn; E H Johnson; V O Speights; M Riggs; M Lind; N Bell
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

7.  Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis.

Authors:  S M Phillips; C M Barton; S J Lee; D G Morton; D M Wallace; N R Lemoine; J P Neoptolemos
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

8.  Proliferative response of human prostate tumour xenografts to surgical trauma and the transurethral resection of the prostate controversy.

Authors:  A E Bogden; D LePage; S Zwicker; W Grant; M Silver
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.